A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-08165784 MONOTHERAPY AND COMBINATIONS IN PARTICIPANTS WITH PIK3CA-MUTATED ADVANCED OR METASTATIC SOLID TUMORS
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients.
This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery.
All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Pfizer CT.gov Call Center
- 電話番号:1-800-718-1021
- メール:ClinicalTrials.gov_Inquiries@pfizer.com
研究場所
-
-
Arkansas
-
Fayetteville、Arkansas、アメリカ、72703
- Highlands Oncology Group, PA
-
Rogers、Arkansas、アメリカ、72758
- Highlands Oncology Group, PA
-
Springdale、Arkansas、アメリカ、72762
- Highlands Oncology Group, PA
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49546
- START Midwest, LLC
-
-
-
-
-
San Juan、プエルトリコ、00935
- Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 years of age or older
- Advanced or metastatic cancer of the breast or colon Part 1A, IB, and 1C: HR+/HER2- advanced or metastatic breast cancer with disease progression after at least 1 line of treatment with an endocrine therapy and CDK4/6 inhibitor in the advanced or metastatic setting and received no more than 1 line of prior cytotoxic and/or 1 line of prior ADC therapy in the metastatic setting Part 1D: Metastatic or advanced colorectal cancer with at least having received chemotherapy and/or targeted therapy if appropriate Part 2A: HR+/HER2- advanced or metastatic breast cancer with no prior systemic therapy or chemotherapy for advanced or metastatic disease
- PIK3CA mutation
- Archived tumor specimen or fresh tumor biopsy
- Measurable disease
- ECOG performance status 0 or 1
Exclusion Criteria:
- Active or clinically significant dermatologic conditions
- Active malignancy within 3 years prior to enrollment
- Advanced/metastatic, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term
- Major surgery or radiation therapy within 3 weeks prior to study entry
- Prior irradiation to >25% of the bone marrow
- Active or history of pneumonitis/interstitial lung disease requiring corticosteroids
- Unmanageable ascites
- Prior treatment with PI3K/AKT/mTOR pathway inhibitors may be permitted in certain study cohorts and excluded in others, as specified by the study protocol.
- Renal impairment
- Hepatic dysfunction
- Hematologic abnormalities
- Uncontrolled diabetes
- Cardiac abnormalities
- Active or history of clinically significant GI or inflammatory GI disease
- Other unacceptable abnormalities or prohibited therapies as defined by protocol
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part 1 Dose Escalation Cohort 1A
PF-08165784 monotherapy dose escalation for participants with advanced or metastatic BC at different doses of the study drug |
Taken by mouth (PO) |
|
実験的:Part 1 Dose Escalation Cohort 1B
Combination (PF-08165784 + fulvestrant) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug |
Selective Estrogen Receptor Degrader (SERD)
他の名前:
Taken by mouth (PO) |
|
実験的:Part 1 Dose Escalation Cohort 1C
Combination (PF-08165784 + fulvestrant + atirmociclib) dose escalation for participants with advanced or metastatic BC, at different doses of the study drug |
Selective Estrogen Receptor Degrader (SERD)
他の名前:
Taken by mouth (PO) Selective CDK4 inhibitor
他の名前:
|
|
実験的:Part 1 Dose Escalation Cohort 1D
Combination (PF-08165784 + cetuximab) dose escalation for participants with advanced or metastatic CRC at different doses of the study drug |
Monoclonal antibody (EGFR inhibitor)
他の名前:
Taken by mouth (PO) |
|
実験的:Part 2 Dose Optimization/Expansion Cohort 2A
Combination (PF-08165784 + letrozole + atirmociclib) dose optimization/expansion for participants with advanced or metastatic BC, at different doses of the study drug |
Taken by mouth (PO) Selective CDK4 inhibitor
他の名前:
Nonsteroidal aromatase inhibitor
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)
時間枠:Baseline up to 28 days
|
Any adverse events that are attributable to one, the other, or both study treatments, occurring in the DLT observation period are considered DLTs, excluding toxicities clearly due to underlying disease or extraneous causes. |
Baseline up to 28 days
|
|
Part 1 (Dose Escalation): Number of participants with laboratory abnormalities
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 2 (Dose Expansion): Objective Response Rate (ORR)
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
ORR defined as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part 2 (Dose Expansion): Number of participants with laboratory abnormalities
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
Number of participants with laboratory test abnormalities. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 2 (Dose Expansion): Incidence of Adverse Events (AEs)
時間枠:From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
An adverse event (AE) was any untoward medical occurrence in a participant who received study medication without regard to possibility of causal relationship to it. |
From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
|
|
Part 1 & Part 2: Disease Control Rate (DCR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
DCR is defined as the proportion of participants with CR or PR with confirmation, or Stable Disease (SD) per RECIST version 1.1. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Clinical Benefit Rate (CBR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
CBR is defined as the percentage of participants with a best overall response of CR or PR at any time before Progressive Disease (PD), or non-CR/non-PD or SD for at least 24 weeks from start date of treatment and prior to PD, relative to the appropriate analysis set. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Duration of Response (DOR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
DOR is defined as the time from first documentation of CR or PR to date of first documentation of PD or death due to any cause. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Progression-Free Survival (PFS) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
PFS is defined as time from start date of treatment to the date of first documentation of PD or death due to any cause. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1 & Part 2: Time to Response (TTR) as per RECIST v1.1
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
TTR is defined as the time from start date of treatment to first documentation of CR or PR. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 2: Overall Survival (OS)
時間枠:Up to approximately 2 years
|
OS is defined as time from from start date of treatment to the date of death due to any cause |
Up to approximately 2 years
|
|
Part 1: Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
時間枠:Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
ORR is defined as the percentage of participants in the analysis population having a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST v1.1. |
Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
|
|
Part 1: Maximum Observed Serum Concentration (Cmax) & Trough Concentration (Ctrough)
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Time to Reach Maximum Observed Serum Concentration (Tmax)
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Area Under the Curve (AUC) from Time Zero to Last Quantifiable Concentration (AUClast)
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the single and multiple dose PK of PF-08165784 as monotherapy, or in combination with other anti-tumor agents. |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on Cmax
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on Cmax of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on Tmax
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on Tmax of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 1: Effect of Food on AUClast
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the effect of food on AUClast of PF-08165784 as monotherapy |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
|
Part 2 (Dose Expansion): Pre- and post-dose concentrations of PF-08165784
時間枠:Baseline through end of Cycle 1 (each cycle is 28 days)
|
Evaluate the pre- and post-dose concentrations of PF-08165784 |
Baseline through end of Cycle 1 (each cycle is 28 days)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 腸の病気
- 組織型別の新生物
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 結腸直腸腫瘍
- 腸の腫瘍
- 新生物、腺および上皮
- 結腸疾患
- 皮膚疾患
- 乳房の病気
- 皮膚および結合組織疾患
- がん
- 結腸新生物
- 乳房腫瘍
- ホルモン
- ホルモン、ホルモン代替品、ホルモン拮抗薬
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- アゾール
- 多環式化合物
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- ステロイド
- 融合リング化合物
- ニトリル
- エストラジオール
- Estrenes
- エストラン
- エストラジオール同族体
- ゴナダルステロイドホルモン
- ゴナダルホルモン
- トリアゾール
- レトロゾール
- フルベストラント
- セツキシマブ
その他の研究ID番号
- C6631001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。